Hot search: floor  new  statistics  healthcare  Port  industrial  wrap  packaging  electric  retailers 
 
Home > News > Market > Content

GSK Has Entered Into a Drug Discovery Alliance with Yale

increase font size  reduce font Add date: 2016-11-30  Hits:94
Core prompt: GlaxoSmithKline (GSK) has entered into a drug discovery alliance with Yale to design a potential new class of medicines that degrade disease-causing proteins. Under the co

GlaxoSmithKline (GSK) has entered into a drug discovery alliance with Yale to design a potential new class of medicines that degrade disease-causing proteins.

Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale's work on proteolysis targeting chimeric molecules (PROTACs).

The PROTAC technology directs disease-causing proteins to a cell's garbage disposal where they can be destroyed.

Yale will be eligible for milestone and royalty payments for each protein-degrading drug that is discovered and developed, as per the agreement.

GSK Protein Degradation effort head Kris Famm said, "This partnership is exploring a new way for promising, but unproven therapeutic approaches to jump from the academic lab more quickly into the early stage pharmaceutical pipeline.

 
 
[ NewsSearch ]  [ Send Fav ]  [ Share ]  [ Print ]  [ Send Report ]  [ Close ]

 
Total0bar [View All]  Related Comments

 
Photo Recommended
Recommend News
Click Rank
 
Home | Products | Suppliers | News | Tradeshow | Sitemap | Message | RSS Feed